23806-24-8 Usage
Description
3-Methyl-2-thiophenecarboxylic acid is an organic compound that is characterized by its white to light yellow crystal powder appearance. It has been utilized in the synthesis of various metal carboxylate complexes, such as those involving zinc and cadmium. 3-Methyl-2-thiophenecarboxylic acid plays a significant role in the field of coordination chemistry and material science due to its ability to form stable complexes with metal ions.
Uses
Used in Coordination Chemistry:
3-Methyl-2-thiophenecarboxylic acid is used as a ligand in coordination chemistry for the formation of metal carboxylate complexes. Its application is based on its ability to chelate with metal ions, providing stability and unique properties to the resulting complexes.
Used in Material Science:
In the field of material science, 3-Methyl-2-thiophenecarboxylic acid is used as a building block for the synthesis of metal-organic frameworks (MOFs) and other coordination polymers. The application reason is its capacity to form extended structures with metal ions, which can exhibit interesting properties such as magnetism, conductivity, or gas adsorption.
Used in Pharmaceutical Industry:
3-Methyl-2-thiophenecarboxylic acid is used as an intermediate in the synthesis of various pharmaceutical compounds. Its application is due to its reactivity and the potential for functionalization, which allows for the development of new drugs with specific therapeutic properties.
Used in Chemical Synthesis:
3-Methyl-2-thiophenecarboxylic acid is used as a starting material or intermediate in the synthesis of a wide range of organic compounds, including dyes, pigments, and other specialty chemicals. The application reason is its versatile chemical reactivity, which allows for various functional group transformations and the creation of diverse molecular structures.
Synthesis Reference(s)
The Journal of Organic Chemistry, 28, p. 914, 1963 DOI: 10.1021/jo01039a008Tetrahedron Letters, 26, p. 1777, 1985 DOI: 10.1016/S0040-4039(00)98336-9
Check Digit Verification of cas no
The CAS Registry Mumber 23806-24-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,8,0 and 6 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 23806-24:
(7*2)+(6*3)+(5*8)+(4*0)+(3*6)+(2*2)+(1*4)=98
98 % 10 = 8
So 23806-24-8 is a valid CAS Registry Number.
InChI:InChI=1/C6H6O2S/c1-4-2-3-9-5(4)6(7)8/h2-3H,1H3,(H,7,8)/p-1
23806-24-8Relevant articles and documents
Direct carboxylation of thiophenes and benzothiophenes with the aid of EtAlCl2
Nemoto, Koji,Onozawa, Satoru,Konno, Megumi,Morohashi, Naoya,Hattori, Tetsutaro
experimental part, p. 369 - 371 (2012/05/05)
-
Synthesis of N-(Methoxycarbonylthienylmethyl)thioureas and evaluation of their interaction with inducible and neuronal nitric oxide synthase
Suaifan, Ghadeer A.R.Y.,Goodyer, Claire L.M.,Threadgill, Michael D.
experimental part, p. 3121 - 3134 (2010/09/04)
Two isomeric N-(memoxycarbonylmienylmemyl)mioureas were synthesised by a sequence of radical bromination of methylthiophenecarboxylic esters, substitution with trifluoroacetamide anion, deprotection, formation of the corresponding isothiocyanates and addition of ammonia. The interaction of these new thiophene-based thioureas with inducible and neuronal nitric oxide synthase was evaluauted. These novel thienylmethyl- thioureas stimulated the activity of inducible Nitric Oxide Synthase (iNOS).
TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
-
Page 73-74, (2010/02/10)
The present invention relates to tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. More precisely, the present invention relates to tricyclic derivatives as colchicine derivatives, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. Tricyclic derivatives of the present invention show very powerful cytotoxicity to cancer cell lines but were much less toxic than colchicine or taxol, confirmed through animal toxicity test. Tricyclic derivatives of the invention also decrease the volume and weight of a tumor and have a strong angiogenesis inhibiting activity in HUVEC cells. Thus, tricyclic derivatives of the present invention can effectively be used as an anticancer agent, anti-proliferation agent and an angiogenesis inhibitor.
